“I expect that nerandomilast will offer a transformative survival benefit for patients with either IPF or PPF,” said Toby Maher, M.D., Ph.D., Professor of Clinical Medicine, Keck School of Medicine, USC Los Angeles. “In clinical practice, we believe that slowing FVC decline is one important precursor to improving survival in people with IPF and PPF. Data from the FIBRONEER™ trials, plus the survival modeling, are showing us improvements that are truly meaningful, suggesting nerandomilast may have an effect on survival beyond that mediated by reducing decline in FVC.”
